Voices
Jad Chahoud: Rethinking the “Undruggable” TP53 Through Early Clinical Innovation
Jad Chahoud/LinkedIn

Jad Chahoud: Rethinking the “Undruggable” TP53 Through Early Clinical Innovation

Jad Chahoud, Chief Scientific and Innovation Officer at Orlando Health Cancer Institute, shared a post on LinkedIn:

“TP53 is considered the ultimate “undruggable” target. This new NEJM Group phase 1 trial suggests that may be changing:

  • 77 heavily pretreated pts with TP53 Y220C mutant solid tumors
  • First-in-class oral p53 reactivator (rezatapopt)
  • 20% ORR overall
  • 30% ORR in KRAS wild-type at active doses
  • Responses across ovarian, breast & other tumors
  • Mostly grade 1–2 AEs; only 3% discontinued.”

Title: Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors

Authors: Ecaterina E. Dumbrava, Geoffrey I. Shapiro, Aparna R. Parikh, Melissa L. Johnson, Anthony W. Tolcher, John A. Thompson, Anthony B. El-Khoueiry, Andrae L. Vandross, Shivaani Kummar, Dale R. Shepard, Kim LeDuke, Lisa Sheehan, Leila Alland, Arshad Haque, Deepika Jalota, Marc Fellous, Alison M. Schram

Read the Full Article.

Jad Chahoud: Rethinking the “Undruggable” TP53 Through Early Clinical Innovation

Other articles featuring Jad Chahoud on OncoDaily.

 

Alison M. Schram Andrae L. Vandross Anthony B. El-Khoueiry Anthony W. Tolcher Aparna R. Parikh Arshad Haque cancer Dale R. Shepard Deepika Jalota Ecaterina E. Dumbrava Geoffrey I Shapiro Jad Chahoud John A. Thompson Kim LeDuke Leila Alland Lisa Sheehan Marc Fellous Melissa L. Johnson OncoDaily Oncology Shivaani Kummar